The Characterization of Biotherapeutics & Vaccines pipeline features three back-to-back popular conferences on critical topics such as analytical and characterization tools for protein aggregation, stability assessment, detection,
and control of contaminants and impurities in biotherapeutics and vaccines for covid-19 and other diseases. These conferences will feature case studies, new and unpublished data, interactive discussions, panel discussions on strategies and tools for
characterization, risk assessment, and mitigation for protein aggregates, particles, and impurities arising from products, excipients, processes, and packaging in novel biologics and vaccines and mRNA therapies.
January 16-17
Characterization of Biotherapeutics
January 17-18
Characterizing Protein Aggregates and Impurities
January 19-20
Characterization and Development of Vaccines
Keynote Presentations:
Drug-Like Antibodies Generated Using Yeast-Display Screening and Machine Learning
Peter M. Tessier, PhD, Albert M. Mattocks Professor, Pharmaceutical Sciences & Chemical Engineering, University of Michigan
Optimizing Drug Product Presentation and Manufacturing Processes for Gene Therapy Products
Sandeep Yadav, PhD, Senior Director, Drug Product Formulation & Fill/Finish, Sangamo Therapeutics
Personalized Vaccinology: Missed Opportunities during COVID-19; Is It Too Late Now?
John Mattison, Operating Partner/Chief Medical Information Officer, Arsenal Capital Partners
If you are working in the following areas join the PepTalk community:
- Analytical Development
- BioProcess Development
- Formulation development
- Late-Stage Development
- Manufacturing
- Mass Spectrometry
- Material Sciences
- New Product Development
- Pharmaceutics
- Pharmaceutical Development
- Pharmaceutical R&D
- Process Development/Control/Support
- Process & Product Development
- (New) Product Development
- Process Engineering
- Protein Analytics
- Protein Analytical Chemistry
- Purification and Process Development
- QA/QC
- Research & Development